Castle Hook Partners LP Has $24.80 Million Stock Position in Catalent, Inc. (NYSE:CTLT)

Castle Hook Partners LP lowered its position in Catalent, Inc. (NYSE:CTLT - Free Report) by 50.8% in the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 409,419 shares of the company's stock after selling 422,018 shares during the period. Catalent comprises 0.5% of Castle Hook Partners LP's holdings, making the stock its 29th largest position. Castle Hook Partners LP owned 0.23% of Catalent worth $24,799,000 at the end of the most recent quarter.

Several other hedge funds have also added to or reduced their stakes in the business. Nisa Investment Advisors LLC increased its holdings in shares of Catalent by 1.7% in the second quarter. Nisa Investment Advisors LLC now owns 11,013 shares of the company's stock worth $619,000 after acquiring an additional 185 shares in the last quarter. GAMMA Investing LLC increased its stake in Catalent by 25.9% during the 2nd quarter. GAMMA Investing LLC now owns 1,032 shares of the company's stock worth $58,000 after purchasing an additional 212 shares in the last quarter. Sumitomo Mitsui DS Asset Management Company Ltd increased its stake in Catalent by 1.1% during the 3rd quarter. Sumitomo Mitsui DS Asset Management Company Ltd now owns 19,458 shares of the company's stock worth $1,179,000 after purchasing an additional 220 shares in the last quarter. Crossmark Global Holdings Inc. raised its holdings in Catalent by 2.6% during the 3rd quarter. Crossmark Global Holdings Inc. now owns 9,133 shares of the company's stock worth $553,000 after buying an additional 229 shares during the period. Finally, Vanguard Personalized Indexing Management LLC lifted its stake in Catalent by 3.8% in the second quarter. Vanguard Personalized Indexing Management LLC now owns 7,688 shares of the company's stock valued at $432,000 after buying an additional 278 shares in the last quarter.

Insider Activity

In other news, Director Michelle R. Ryan sold 2,800 shares of the company's stock in a transaction dated Monday, November 11th. The shares were sold at an average price of $59.70, for a total value of $167,160.00. Following the sale, the director now directly owns 10,835 shares of the company's stock, valued at approximately $646,849.50. This represents a 20.54 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider David Mcerlane sold 1,994 shares of Catalent stock in a transaction dated Thursday, September 26th. The stock was sold at an average price of $59.97, for a total value of $119,580.18. Following the transaction, the insider now owns 36,304 shares of the company's stock, valued at $2,177,150.88. The trade was a 5.21 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 5,114 shares of company stock valued at $305,931. 0.31% of the stock is owned by insiders.

Catalent Stock Up 0.4 %

Shares of Catalent stock traded up $0.25 during trading hours on Thursday, reaching $61.00. 1,498,729 shares of the company's stock were exchanged, compared to its average volume of 2,036,391. The stock has a market cap of $11.07 billion, a P/E ratio of -26.99, a P/E/G ratio of 2.44 and a beta of 1.16. The company has a 50 day moving average of $59.86 and a two-hundred day moving average of $58.41. The company has a current ratio of 2.51, a quick ratio of 1.96 and a debt-to-equity ratio of 1.38. Catalent, Inc. has a fifty-two week low of $36.74 and a fifty-two week high of $61.50.

Catalent (NYSE:CTLT - Get Free Report) last issued its quarterly earnings results on Tuesday, November 5th. The company reported ($0.13) EPS for the quarter, missing the consensus estimate of $0.05 by ($0.18). The company had revenue of $1.02 billion for the quarter, compared to analyst estimates of $1.06 billion. Catalent had a negative net margin of 9.28% and a negative return on equity of 0.66%. The business's revenue for the quarter was up 4.2% on a year-over-year basis. During the same period last year, the company posted ($0.10) earnings per share. On average, sell-side analysts forecast that Catalent, Inc. will post 0.84 EPS for the current fiscal year.

Wall Street Analyst Weigh In

CTLT has been the topic of a number of research analyst reports. StockNews.com lowered shares of Catalent from a "hold" rating to a "sell" rating in a report on Friday, November 22nd. William Blair restated a "market perform" rating on shares of Catalent in a report on Tuesday, September 3rd. Baird R W downgraded Catalent from a "strong-buy" rating to a "hold" rating in a report on Tuesday, September 24th. Finally, Robert W. Baird reissued a "neutral" rating and issued a $63.50 target price on shares of Catalent in a research report on Tuesday, September 24th. One analyst has rated the stock with a sell rating and seven have given a hold rating to the stock. Based on data from MarketBeat, Catalent currently has a consensus rating of "Hold" and an average target price of $63.40.

Catalent Company Profile

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.